z-logo
open-access-imgOpen Access
Azathioprine for prevention of postoperative recurrence in Crohn's disease
Author(s) -
Simon Travis
Publication year - 2001
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/00042737-200111000-00001
Subject(s) - medicine , azathioprine , thiopurine methyltransferase , crohn's disease , mercaptopurine , pharmacotherapy , disease , surgery , prospective cohort study
The clinical relapse rate after surgery for Crohn's disease in prospective studies is about 40% at 2 years in people who receive no postoperative prophylaxis. Thiopurines (azathioprine and 6-mercaptopurine) are likely to be the most effective pharmacotherapy for preventing postoperative relapse: about four patients need to be treated for 2 years to prevent one clinical relapse. The factors that help to identify patients at highest risk of relapse are discussed, along with the reasons for the choice of thiopurine, dose and duration of therapy. Other measures to reduce the relapse rate are addressed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here